Compare WEYS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEYS | ACRS |
|---|---|---|
| Founded | 1906 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.9M | 230.8M |
| IPO Year | N/A | 2015 |
| Metric | WEYS | ACRS |
|---|---|---|
| Price | $30.06 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 20.8K | ★ 1.4M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $279,843,000.00 | $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.51 | $1.05 |
| 52 Week High | $38.24 | $4.24 |
| Indicator | WEYS | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 64.58 |
| Support Level | $28.69 | $2.34 |
| Resistance Level | $30.73 | $2.57 |
| Average True Range (ATR) | 1.35 | 0.21 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 37.48 | 87.31 |
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.